Venous Thromboembolism Clinical Trial
— VTEOfficial title:
Venous Thromboembolism Prophylaxis in a Tertiary UAE Hospital: Comparison of Clinical Practice Guidelines.
Study Title:Assessment of Adherence to Guidelines for Thromboprophylaxis in a Tertiary
United Arab Emirates (UAE) hospital
Study Site: Al Qassimi Hospital, United Arab Emirates
Study Objectives:
The primary objective of this study is assessment of appropriateness of VTE prophylaxis
administered to critically ill and surgical patients for whom pharmacologic treatment is
indicated according to the American College of Chest Physicians (ACCP) 2012 guidelines.
The secondary objective is to:
1.Identify some causes of inadequate VTE prophylaxis in different patient populations, such
as prescribing problems and errors at the level of administration.
Study Design: Cross sectional retrospective observational study
Sample size: Approximately 400
Study Population:
Inclusion criteria
Patients who meet the following criteria will be included:
1. Patients aged 18 and above.
2. Patients admitted to any of the critical care units, or the general or orthopaedic
surgical wards.
3. Patients who have been in hospital more than 24 hours.
4. Caprini score > 1 (see procedure)
Exclusion criteria
Patients with any of the following criteria will be excluded:
1. Patients who have been admitted to a critical care unit and transferred out to a non
surgical unit within 24 hours of admission.
2. Patients receiving oral anticoagulant therapy for indications other than VTE
prophylaxis or treatment, such as atrial fibrillation and prosthetic heart valves.
Study Outcome Measurements:
The main outcome measure of interest is to determine the proportion of patients who have
received inappropriate or inadequate VTE prophylaxis considering their calculated risk
factor compared to the recommended prophylactic measures for that risk.
Secondary outcome measures are to identify whether there is inadequate VTE prophylaxis
because of medication errors such as missed doses or wrong doses given.
Study Duration: 4 months
Statistical Analysis Data was entered into Microsoft Excel® and subsequently checked to
ensure accurate data entry and correct any errors. It was subsequently exported into SPSS
version 20 where it will be analysed.Quantitative data such as age was expressed mean (±
standard deviation). Categorical data such as gender, risk factors for bleeding, type of
mechanical and pharmacologic prophylaxis, missed doses and wrong doses were expressed as
number and percentage of population.The student's t-test was used to analyse parametric
data. The Pearson Chi-Square Test and Wilcoxon Rank sum test were used to analyse non
parametric data. Simple and multiple logistic regression analysis was done to identify
factors that are associated with inappropriate VTE prophylaxis. Factors that were included
in the analysis included: age, type of admission (medical or surgical), area of admission
(critical care, general surgery, orthopaedic surgery), Caprini score, and inappropriate VTE
prophylaxis as the outcome. A p-value of less than 0.05 was be considered statistically
significant.
Status | Completed |
Enrollment | 386 |
Est. completion date | September 2013 |
Est. primary completion date | August 2013 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: 1. Patients aged 18 and above. 2. Patients admitted to any of the critical care units, or the general or orthopaedic surgical wards. 3. Patients who have been in hospital more than 24 hours. 4. Caprini score > 1 (see procedure) Exclusion Criteria: 1. Patients who have been admitted to a critical care unit and transferred out to a non surgical unit within 24 hours of admission. 2. Patients receiving oral anticoagulant therapy for indications other than VTE prophylaxis or treatment, such as atrial fibrillation and prosthetic heart valves. |
Time Perspective: Retrospective
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Ministry of Health, United Arab Emirates |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of patients receiving inappropriate or inadequate VTE prophylaxis | Case Report Form Analysis Form | 2 weeks | No |
Secondary | Number of patients receiving inadequate VTE prophylaxis due to medication errors, missed doses etc. | Case Report Form Analysis Form | 2 weeks | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05347550 -
Examining the Benefit of Graduated Compression Stockings in the Prevention of vEnous Thromboembolism in Low-risk Surgical Patients
|
N/A | |
Enrolling by invitation |
NCT05794165 -
Antithrombin to Improve Thromboprophylaxis and Reduce the Incidence of Trauma-Related Venous Thromboembolism
|
Phase 2 | |
Completed |
NCT02379806 -
The SYMPTOMS - SYstematic Elderly Medical Patients Thromboprophylaxis: Efficacy on Symptomatic OutcoMeS - Study
|
Phase 3 | |
Recruiting |
NCT03691753 -
Safety and Efficacy Study of Fitaya Vena Cava Filter
|
N/A | |
Completed |
NCT02197416 -
Safety of Dabigatran Etexilate in Blood Clot Prevention in Children
|
Phase 3 | |
Recruiting |
NCT05378035 -
DOAC in Chinese Patients With Atrial Fibrillation
|
||
Recruiting |
NCT05171075 -
A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE
|
Phase 3 | |
Completed |
NCT01895777 -
Open Label Study Comparing Efficacy and Safety of Dabigatran Etexilate to Standard of Care in Paediatric Patients With Venous Thromboembolism (VTE)
|
Phase 3 | |
Completed |
NCT05897697 -
Assessing Women's Preferences for Postpartum Thromboprophylaxis: the Prefer-Postpartum Study
|
||
Completed |
NCT04735523 -
Replication of the RECOVER-II Anticoagulant Trial in Healthcare Claims Data
|
||
Completed |
NCT04736719 -
Replication of the AMPLIFY Anticoagulant Trial in Healthcare Claims Data
|
||
Completed |
NCT04736420 -
Replication of the EINSTEIN-DVT Anticoagulant Trial in Healthcare Claims Data
|
||
Completed |
NCT02746185 -
Cancer Associated Thrombosis, a Pilot Treatment Study Using Rivaroxaban
|
Phase 3 | |
Completed |
NCT02912234 -
Effect of Clarithromycin on the Pharmacokinetics of Apixaban in Healthy Participants
|
Phase 1 | |
Completed |
NCT02829957 -
RAMBLE - Rivaroxaban vs. Apixaban for Heavy Menstrual Bleeding
|
Phase 2/Phase 3 | |
Completed |
NCT02334007 -
Extended Low-Molecular Weight Heparin VTE Prophylaxis in Thoracic Surgery
|
Phase 1/Phase 2 | |
Completed |
NCT02223260 -
Tolerability , PK/PD and Safety of Dabigatran Etexilate Oral Liquid Formulation in Children < 1 Year of Age
|
Phase 2 | |
Completed |
NCT02661568 -
Description of Patients With Acute Venous Thromboembolism in the UK's Clinical Practice Research Datalink Linked With Hospital Episode Statistics Dataset (CPRD-HES)
|
N/A | |
Completed |
NCT01431456 -
Safety of DAbigatran and RIvaroxaban Versus NAdroparin in the Prevention of Venous Thromboembolism After Knee Arthroplasty Surgery
|
Phase 3 | |
Completed |
NCT01972243 -
Risk of Recurrent Venous Thrombosis: A Validation Study of the Vienna Prediction Model
|